Abstract

BackgroundEffective control of schistosomiasis remains a challenging problem for endemic areas of the world. Given knowledge of the biology of transmission and past experience with mass drug administration (MDA) programs, it is important to critically evaluate the likelihood that MDA programs will achieve substantial reductions in Schistosoma prevalence. In implementing the World Health Organization Roadmap for Neglected Tropical Diseases it would useful for policymaking to model projections of the status of Schistosoma control in MDA-treated areas in the next 5–10 years.MethodsCalibrated mathematical models were used to project the effects of different frequency and coverage of MDA for schistosomiasis haematobia control in present-day endemic communities, taking into account uncertainties of parasite biology and input data. The modeling approach in this analysis was the Stratified Worm Burden model developed in our earlier works, calibrated using data from longitudinal S. haematobium control trials in Kenya.ResultsModel-based simulations of MDA control in typical low-risk and higher-risk communities indicated that infection prevalence can be substantially reduced within 10 years only when there is a high degree of community participation (>70 %) with at least annual MDA. Significant risk for re-emergence of infection remains if MDA is suspended.ConclusionsIn a stable (stationary) ecosystem, Schistosoma reproduction and transmission are sufficiently robust that the process of human infection continues, even under pressure from aggressive MDA. MDA alone is unlikely to interrupt transmission, and once mass treatment is suspended, the prevalence of human infection is likely to rebound to pre-control levels over a period of 25–30 years. MDA success in achieving very low levels of infection prevalence is highly dependent on treatment coverage and frequency within the local human population, and requires that both adults and children be included in drug delivery coverage. Ultimately, supplemental snail control and significant improvements in sanitation will be required to achieve full control of schistosomiasis by elimination of ongoing Schistosoma transmission.Electronic supplementary materialThe online version of this article (doi:10.1186/s13071-015-1144-3) contains supplementary material, which is available to authorized users.

Highlights

  • Effective control of schistosomiasis remains a challenging problem for endemic areas of the world

  • The questions posed for the current modeling analysis are: Given what is known about the biology of parasite transmission, and given past experience with participation in mass drug administration (MDA) programs, how likely are we to achieve substantial reductions in Schistosoma prevalence, and over what time period? In particular, what will be the likely status of Schistosoma control in treated areas in the year 2020?

  • Our model simulations suggest the following conclusions about the currently advocated preventive chemotherapy (PCT) programs: In a stable transmission ecosystem, Schistosoma reproduction and transmission are sufficiently robust that the process of human infection continues, even under pressure from aggressive MDA

Read more

Summary

Introduction

Effective control of schistosomiasis remains a challenging problem for endemic areas of the world. National and international schistosomiasis control programs are currently focused on expanding the use of mass drug administration (MDA) of the anti-schistosomal drug praziquantel to minimize infection-induced morbidity by reducing infection intensity among school-age children and high-risk adult populations [4]. This approach, termed preventive chemotherapy (PCT), has its limitations, in that parasite transmission can continue to occur, leaving populations at risk for reinfection and recurrent risk for disease [5,6,7,8,9]. The questions posed for the current modeling analysis are: Given what is known about the biology of parasite transmission, and given past experience with participation in MDA programs, how likely are we to achieve substantial reductions in Schistosoma prevalence, and over what time period? In particular, what will be the likely status of Schistosoma control in treated areas in the year 2020?

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call